Publication:
The impact of cytogenetic aberrations in the clonal evolution of chronic myeloid leukemia: a single-center experience among 450 Turkish patients cohort study

dc.contributor.coauthorIşık, S.
dc.contributor.coauthorGünden, G.
dc.contributor.coauthorÜsküdar, Teke H.
dc.contributor.coauthorOğuz Davutoğlu, N.
dc.contributor.coauthorAslan, V.
dc.contributor.coauthorKaragülle, M.
dc.contributor.coauthorÖzen, H.
dc.contributor.coauthorÇilingir, O.
dc.contributor.coauthorArtan, S.
dc.contributor.coauthorDurak Aras, B.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkay, Olga Meltem
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:46:28Z
dc.date.issued2022
dc.description.abstractObjective: Chronic myeloid leukemia (CML) is a clonal hematologic disorder characterized by t(9;22) translocation, in which cytogenetic aberrations can occur in Ph(+) and (-) clones. These aberrations develop due to clonal evolution as well as treatment and they have prognostic significance. They are grouped as major and minor route anomalies in terms of their effects on prognostic parameters, such as treatment response, overall survival (OS), disease stage, complete cytogenetic response (CCyR), and major molecular response (MMR). It is stated that major route anomalies have unfavorable prognostic effects compared to minor route anomalies. We aimed to investigate the frequency and prognostic effects of cytogenetic anomalies detected in Ph(+) and (-) clones.Materials and methods: in this study, we retrospectively analyzed the cytogenetic results of 450 patients diagnosed with CML between 2005 and 2020.Results: we detected cytogenetic aberrations in Ph-positive and negative clones in 41 of 450 patients. The most common anomalies were trisomy 8 (+8), additional Ph chromosome (+Ph), and loss of chromosome Y. Rarely, aneuploidy of the Y chromosome, dup (22), +11, and +6 were seen in CML patients. We observed that these identified aberrations negatively affected MMR and CCyR, and generally resulted in changing imatinib treatment for second-generation tyrosine kinase activity inhibitors. Our results are compatible with the literature.Conclusion: we suggest that cytogenetic aberrations detected in Ph(+) and (-) clones should be a warning sign in terms of treatment and require close observation. The use of cytogenetic methods for the identification of these anomalies is also important. / Amaç: Kronik myeloid lösemi (KML), t(9;22) ile karakterize olan, Ph(+) ve (-) klonlarda sitogenetik aberasyonların gelişebildiği bir lösemi tipi olarak bilinmektedir. Bu aberasyonlar klonal evolüsyon ve tedaviye bağlı gelişmekte olup, prognostik etkileri olduğu bilinmektedir. Literatürde; tedavi yanıtı, toplam sağkalım (OS), hastalık evresi, tam sitogenetik yanıt (TSY) ve majör moleküler yanıt (MMY) gibi prognostik parametreler üzerine olan etkileri açısından bu anomaliler majör ve minör yolak anomalileri olarak gruplandırılmaktadır. Majör yolak anomalilerinin minör yolak anomalilerine göre prognozu olumsuz yönde etkilediği belirtilmektedir. Biz de, Ph(+) ve (-) klonda saptanan sitogenetik anomalilerin sıklığını ve prognostik etkisini araştırmayı amaçladık. Gereç ve yöntemler: bu çalışmada, 2005-2020 yılları arasında KML tanısı almış 450 hastanın retrospektif olarak sitogenetik sonuçlarını inceledik. Bulgular: bu hastaların 41/450’ inde Ph(+) ve/veya (-) klonda sitogenetik aberasyonlar saptadık. En sık gözlenen anomaliler trizomi 8 (+8), ek Ph kromozomu (+Ph) ve Y kromozom kaybı idi. Ayrıca KML hastalarında nadir görülen dup (22), +11, +6 ve Y kromozom artışı; ve daha önce literatürde saptanmayan inv(1) anomalisini tespit ettik. Saptanan bu aberasyonların MMY ve TSY olumsuz etkilediğini ve tedavide de genellikle 2. nesil tirozin kinaz aktivite inhibitörlerin tercih edildiğini gözledik. Elde ettiğimiz sonuçlar, literatür verileri ile uyumluluk göstermektedir.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeNational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume39
dc.identifier.doi10.4274/tjh.galenos.2022.2022.0045
dc.identifier.eissn1308-5263
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR04053
dc.identifier.issn1300-7777
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85143088406
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2477
dc.identifier.wos893193800001
dc.keywordsChronic myeloid leukemia
dc.keywordsClonal evolution
dc.keywordsCytogenetics
dc.keywordsPhiladelphia chromosome
dc.keywordsPrognostic aberrations / Kronik myeloid lösemi
dc.keywordsSitogenetik
dc.keywordsKlonal evrim
dc.keywordsPrognostik aberasyon
dc.keywordsPhiladelphia kromozomu
dc.language.isoeng
dc.publisherGalenos Yayınevi
dc.relation.grantnoNA
dc.relation.ispartofTurkish Journal of Hematology
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10931
dc.subjectHematology
dc.titleThe impact of cytogenetic aberrations in the clonal evolution of chronic myeloid leukemia: a single-center experience among 450 Turkish patients cohort study
dc.title.alternativeKronik myeloid löseminin klonal evolüsyonunda sitogenetik aberasyonların etkisi: 450 Türk hastadan oluşan kohort çalışmasında tek merkez deneyimi
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAkay, Olga Meltem
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10931.pdf
Size:
466.4 KB
Format:
Adobe Portable Document Format